{4-[(5-chloro-thiophen-2-ylmethyl)-(methyl)amino]-2-methoxy-phenyl}-carbamic acid propyl ester

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: {4-[(5-chloro-thiophen-2-ylmethyl)-(methyl)amino]-2-methoxy-phenyl}-carbamic acid propyl ester
• 英文别名: propyl N-[4-[(5-chlorothiophen-2-yl)methyl-methylamino]-2-methoxyphenyl]carbamate
• 化学式: C₁₇H₂₁ClN₂O₃S
• 分子量: 368.884
• InChiKey: AQNFKJPGVQANSC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  24
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  79
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• [EN] SUBSTITUTED P-DIAMINOBENZENE DERIVATIVES<br/>[FR] DERIVES DE PARA-DIAMINOBENZENE SUBSTITUES
  申请人：LUNDBECK & CO AS H

  公开号：WO2004082677A1

  公开（公告）日：2004-09-30

  The present invention relates to aniline derivatives of the general formula I or pharmaceutically acceptable salts thereof and their use.

  本发明涉及通式I的苯胺衍生物或其药学上可接受的盐及其用途。
• [EN] PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS<br/>[FR] DERIVES DE PYRAZOLE SERVANT DE MODULATEURS DE PROTEINE KINASE
  申请人：ASTEX TECHNOLOGY LTD

  公开号：WO2005061463A1

  公开（公告）日：2005-07-07

  The invention provides compounds of the formula: (I) having protein kinase B inhibiting activity: wherein A is a saturated hydrocarbon linker group containing from 1 to 7 carbon atoms, the linker group having a maximum chain length of 5 atoms extending between Rl and NR2R3 and a maximum chain length of 4 atoms extending between E and NR2R3, wherein one of the carbon atoms in the linker group may optionally be replaced by an oxygen or nitrogen atom; and wherein the carbon atoms of the inker group A may optionally bear one or more substituents selected from oxo, fluorine and hydroxy, provided that the hydroxy group when present is not located at a carbon atom a with respect to the NR2R3 group and provided that the oxo group when present is located at a carbon atom a with respect to the NR2R3 group; E is a monocyclic or bicyclic carbocyclic or heterocyclic group; Rl is an aryl or heteroaryl group; and R2, R3, R4 and R5 are as defined in the claims. Also provided are pharmaceutical compositions containing the compounds, methods for preparing the compounds and their use as anticancer agents.

  该发明提供了具有蛋白激酶B抑制活性的化合物，其化学式为：（I），其中A是一个饱和的含有1至7个碳原子的烷基链连接基团，该连接基团在R1和NR2R3之间延伸的最大链长为5个原子，在E和NR2R3之间延伸的最大链长为4个原子，其中连接基团中的一个碳原子可以选择性地被氧原子或氮原子取代；连接基团A的碳原子可以选择性地携带来自酮基、氟和羟基的一个或多个取代基，前提是当存在羟基时，该羟基不位于相对于NR2R3基团的碳原子a处，且当存在酮基时，该酮基位于相对于NR2R3基团的碳原子a处；E是一个单环或双环的碳环或杂环基团；R1是芳基或杂芳基团；R2、R3、R4和R5如权利要求中所定义。还提供了含有这些化合物的药物组合物，制备这些化合物的方法以及它们作为抗癌剂的用途。
• Substituted p-diaminobenzene derivatives
  申请人：Khanzhin Nikolay

  公开号：US20060183791A1

  公开（公告）日：2006-08-17

  The present invention relates to aniline derivatives of the general formula I or pharmaceutically acceptable salts thereof and their use.

  本发明涉及一般式I的苯胺衍生物或其药学上可接受的盐及其用途。
• Use of KCNQ-Openers for Treating or Reducing the Symptoms of Schizophrenia
  申请人：H. Lundbeck A/S

  公开号：EP2554162A1

  公开（公告）日：2013-02-06

  The invention relates to a novel method for treating or reducing the symptoms of schizophrenia, said method comprising administering to a host in need thereof an effective amount of a compound able to selectively increase the ion flow through KCNQ potassium channels. Furthermore the invention relates to the use of selective KCNQ potassium channel openers for the preparation of a pharmaceutical composition for treating or reducing the symptoms of schizophrenia and related symptoms, disorders and diseases. Furthermore the invention relates to a method of screening for a compound, which is a selective KCNQ potassium channel opener and which is capable of having an anti-psychotic potential.

  本发明涉及一种治疗或减轻精神分裂症症状的新方法，所述方法包括向有需要的宿主施用有效量的能够选择性地增加通过 KCNQ 钾通道的离子流的化合物。此外，本发明还涉及选择性 KCNQ 钾通道开放剂用于制备治疗或减轻精神分裂症症状及相关症状、紊乱和疾病的药物组合物。此外，本发明还涉及一种筛选化合物的方法，该化合物是一种选择性 KCNQ 钾通道开启剂，具有抗精神病的潜力。
• EP1613303A1
  申请人：——

  公开号：EP1613303A1

  公开（公告）日：2006-01-11